Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common gut drug clear brain fog in liver patients?

NCT ID NCT05754996

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether nifuroxazide, a drug used for gut infections, can help treat hepatic encephalopathy—a condition where liver disease causes confusion and brain fog. Researchers gave the drug to 80 hospitalized patients with moderate to severe symptoms. The goal was to see if it could reverse the brain symptoms faster than standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nifuroxazide
What this could lead to
If it works, nifuroxazide could offer a new treatment option for hepatic encephalopathy, potentially improving mental status and reducing hospital stays.
What could go wrong
This is a small pilot study with only 80 participants, so results may not apply to everyone. Side effects like abdominal pain, nausea, and headache are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

80 people

The number who actually took part.

Started

Mar 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients suffering from liver cirrhosis aging above 18 years who will be admitted to hospital with neuropsychiatric condition suggestive of hepatic encephalopathy (grade II or III) confirmed by their known previous hepatic disease by history, clinical examination and laboratory investigations in the form of hyperammonemia with Model for End-Stage Liver Disease (MELD) score ≤ 25 and patients are able to swallow. Exclusion Criteria: * Patients with neurological or communication problems. * Degenerative central nervous system (CNS) disease. * Any significant psychiatric illness. * Patients with previous intake of nifuroxazide and rifaximin within the last month. * Presence of underlying renal impairment (serum creatinine ≥ 2 mg/dL). * Alcohol consumption within prior 4 weeks. * Non-hepatic metabolic encephalopathy. * Anemia with hemoglobin level \< 7 g/dL.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic encephalopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver hepatic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic encephalopathy

Contacts and locations

Locations

  • National Hepatology and Tropical Medicine Research Institute (NHTMRI)

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.